Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Progesterone in the Treatment of Acute Hemorrhagic Stroke

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Lyen an sove nan clipboard la
EstatiPoko rekrite
Patwone
Second Affiliated Hospital, School of Medicine, Zhejiang University
Kolaboratè
Korea University Anam Hospital
Seoul National University Hospital
Lishui Country People's Hospital
Jinhua Central Hospital
Huizhou Municipal Central Hospital
The Affiliated Hospital of Hangzhou Normal University

Mo kle

Abstrè

A large number of preclinical studies have confirmed that progesterone and its metabolites have strong neuroprotective effects. As a neuroprotective agent, progesterone has been effective in several animal models of nerve injury, suggesting that the drug has a wide range of neuroprotective effects. Pharmacodynamic studies have shown that some characteristic mechanisms of the action of the neurosteroid on brain injury and cerebral congestion include: prevention of inflammatory reaction and cell death (by inhibiting the activation of inflammatory cytokines and microglia); control of angiogenic brain edema (by reestablishing blood-brain barrier and regulating aquaporin-4 water transporter) and cytotoxic edema (by regulating Progesterone can also improve the neural dysfunction after cerebral hemorrhage, promote the regeneration and repair of damaged axons (activate PI3K / Akt pathway to inhibit the expression of RhoA), prevent the loss of Ca2 + caused by excitotoxicity and improve the survival rate of neurons. It was found that progesterone injection could reduce brain edema and promote the recovery of nerve function after brain injury.

Deskripsyon

The purpose of this clinical trial is to further evaluate the safety and effectiveness of progesterone in the clinical application of major cerebral congestion diseases. The Second Affiliated Hospital of Zhejiang University is the unit in charge of clinical research, and six units participate in the multicenter randomized, double-blind, placebo-controlled clinical trial.

Dat

Dènye verifye: 09/30/2019
Premye Soumèt: 10/14/2019
Enskripsyon Estimasyon Soumèt: 10/26/2019
Premye afiche: 10/28/2019
Dènye Mizajou Soumèt: 11/24/2019
Dènye Mizajou afiche: 11/26/2019
Dat aktyèl kòmanse etid la: 01/31/2020
Dat Estimasyon Prensipal Estimasyon an: 10/30/2020
Dat estime fini etid la: 12/30/2020

Kondisyon oswa maladi

Stroke

Entèvansyon / tretman

Drug: experimental group

Other: control grou

Faz

Faz 4

Gwoup bra

BraEntèvansyon / tretman
Experimental: experimental group
Progesterone
Drug: experimental group
intramuscular injection intranasal administration
Placebo Comparator: control grou
saline
Other: control grou
intramuscular injection intranasal administration

Kritè kalifikasyon yo

Laj ki kalifye pou etid 40 Years Pou 40 Years
Sèks ki kalifye pou etidAll
Aksepte Volontè HealthyWi
Kritè

Inclusion Criteria:

- Acute hemorrhagic stroke was confirmed by CT or MRI. There should be no obvious sequelae symptoms in the first stroke or previous stroke, Mrs < 2 (slight or no neurological dysfunction).

- Patients aged 40-80 (male, menopausal women);

- Patients with 6-48 hours of onset;

- 3 points ≤ NIHSS score ≤ 15 points for light and medium patients;

- Patients or family members sign informed consent.

Exclusion Criteria:

- Cerebral CT has excluded intracranial hemorrhage, and there is no imaging change of early large area cerebral infarction.

- Pregnant or lactating women;

- Previous intracranial hemorrhage, including suspected subarachnoid hemorrhage; large area stroke (> 2 / 3 MCA territory) or head CT showed any degree of midline displacement due to brain edema. Signs of intracranial hemorrhage (ICH, SAH, extradural hemorrhage, acute or chronic SDH) were found on baseline CT or MRI scan.

- Fever, defined as central body temperature > 37.5 ℃;

- Patients with severe heart, liver and kidney dysfunction or severe diabetes;

- Platelet count was less than 100 × 109 / L, blood glucose was less than 27 mmol / L, serum creatinine was more than 2.0 mg / dL or 180 μ mol / L.

- Blood pressure: systolic pressure > 180 mmHg, or diastolic pressure > 100 mmHg;

- Those who have previous allergic history to progesterone and citicoline;

- The anticoagulant has been taken orally, and INR is more than 15; heparin has been taken within 48 hours (APTT is beyond the normal range);

- Participating in clinical trials of any other treatment;

- Patients considered by the researchers not suitable for inclusion.

Rezilta

Mezi Rezilta Prensipal yo

1. Modified Rankin Scale [3 month]

The percentage of patients with Mrs score 0, 1 and 2 was compared.

Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge